The effects of FASN-targeted therapy by orlistat combined either with enzalutamide or castration could down-regulate the activity of NF-κB, which was closely associated with phosphorylations of AKT and ERK, resulting in tumor growth inhibition in AIPC. The gene discussed is AKT1; the disease is neoplasm.